IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. (IDXX) Revenue

Alert me on Revenue

IDEXX Laboratories, Inc.'s revenue for fiscal 2025 was $4.3B, up 10.4% from $3.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.6B. Over the past ten years it has ranged from $1.6B (fiscal 2015) to $4.3B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 9th of 50 Diagnostics & Research companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $4.3B 10.42%
FY2024 $3.9B 6.46%
FY2023 $3.7B 8.72%
FY2022 $3.4B 4.73%
FY2021 $3.2B 18.79%
FY2020 $2.7B 12.45%
FY2019 $2.4B 8.75%
FY2018 $2.2B 12.40%
FY2017 $2.0B 10.91%
FY2016 $1.8B 10.83%

Quarterly newest first

Period Revenue Change
Jun 2026 $1.2B 6.64%
Mar 2026 $1.1B 4.61%
Dec 2025 $1.1B (1.33%)
Sep 2025 $1.1B (0.38%)
42 more quarters

Against its own ten years

Low $1.6B High $4.3B
Ten-year median $2.7B
Current reading's percentile 100

Revenue against peers

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on IDXX